Quadrant Pharmaceuticals Issues Class 4 Medicines Defect Notification for Vesomni Tablets
The Class 4 Medicines Defect Notification for Vesomni tablets indicates a significant regulatory issue that could disrupt distribution and patient access. This situation necessitates close monitoring to assess its impact on market dynamics and compliance requirements.
Company
Quadrant Pharmaceuticals
Asset
Vesomni
Indication
Urology / Overactive Bladder
Status
Under Review
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The Class 4 Medicines Defect Notification for Vesomni tablets indicates a significant regulatory issue that could disrupt distribution and patient access. This situation necessitates close monitoring to assess its impact on market dynamics and compliance requirements.
Why it matters
The Class 4 Medicines Defect Notification for Vesomni tablets indicates a significant regulatory issue that could disrupt distribution and patient access. This situation necessitates close monitoring to assess its impact on market dynamics and compliance requirements.
What changed
Safety Signal
Analysis
Quadrant Pharmaceuticals has reported Class 4 Medicines Defect due to incorrect barcode/GTIN on Vesomni tablets.
The Class 4 Medicines Defect Notification for Vesomni tablets indicates a significant regulatory issue that could disrupt distribution and patient access. This situation necessitates close monitoring to assess its impact on market dynamics and compliance requirements.
Monitor for updates on the resolution of the defect and any regulatory actions taken by the MHRA.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.